86 related articles for article (PubMed ID: 15548437)
1. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
[TBL] [Abstract][Full Text] [Related]
2. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
[TBL] [Abstract][Full Text] [Related]
4. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
6. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
7. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W; Ackler J; Tijani L; Leighton J
Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
[TBL] [Abstract][Full Text] [Related]
10. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ; Guerra ML; Kronish L
Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
19. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Petrioli R; Paolelli L; Francini E; Manganelli A; Salvestrini F; Francini G
Urology; 2007 Jan; 69(1):142-6. PubMed ID: 17270637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
